P13K/AKT/mTOR Pathway-Based Novel Biomarkers for Breast Cancer
Background: Breast cancer has been the most recurrent frequent cause of cancer-related deaths in women in India and all around the world. The treatment options have been reportedly more effective in terms of cure at the initial stages of diagnosis, while at the advanced stages, the treatment still r...
| Main Authors: | , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Mary Ann Liebert
2021-01-01
|
| Series: | Re:GEN Open |
| Subjects: | |
| Online Access: | https://www.liebertpub.com/doi/full/10.1089/REGEN.2021.0015 |
| _version_ | 1797346084290297856 |
|---|---|
| author | Varruchi Sharma Anil Panwar Anil K. Sharma |
| author_facet | Varruchi Sharma Anil Panwar Anil K. Sharma |
| author_sort | Varruchi Sharma |
| collection | DOAJ |
| description | Background: Breast cancer has been the most recurrent frequent cause of cancer-related deaths in women in India and all around the world. The treatment options have been reportedly more effective in terms of cure at the initial stages of diagnosis, while at the advanced stages, the treatment still remains a great clinical challenge. Many targeted therapies have been reported earlier, which have given impetus to find novel therapies that may lead to increased survival rates in breast cancer patients.
Methodology: The available literature using PubMed, Scopus and Google Scholar database was thoroughly reviewed using the keywords: breast cancer; P13K/AKT/mTOR; inhibitors; therapeutics; biomarkers and diagnosis. This narrative review of all the relevant papers with significant citations leads the authors to greater insight into the potential therapeutics against breast cancer.
Results: In most breast cancers, the essential phosphoinositide-3-kinase/AKT/ mammalian rapamycin target (PI3K/AKT/mTOR) signalling pathway has reportedly been triggered, leading to excessive cell growth and tumor formation. The targeting of this important pathway is, therefore, an area of wide-clinical interest, particularly in the breast cancer treatment. Taking these details into account, the current review has reviewed preclinical and clinical studies where a variety of PI3K/Akt/mTOR pathway inhibitors (acting at different levels) have been used either alone or in conjunction with other cancer treatment agents.
Conclusion: This review includes a detailed understanding of the structure and regulation/deregulation of mTOR, in addition to targeted therapies and the role of mTOR inhibitory drugs in the treatment of breast cancer, along with first and second generations PI3K/AKT/mTOR pathway inhibitors |
| first_indexed | 2024-03-08T11:26:43Z |
| format | Article |
| id | doaj.art-5021b712c7ab49caa2ae87c99b02f8bc |
| institution | Directory Open Access Journal |
| issn | 2766-2705 |
| language | English |
| last_indexed | 2024-03-08T11:26:43Z |
| publishDate | 2021-01-01 |
| publisher | Mary Ann Liebert |
| record_format | Article |
| series | Re:GEN Open |
| spelling | doaj.art-5021b712c7ab49caa2ae87c99b02f8bc2024-01-26T05:12:17ZengMary Ann LiebertRe:GEN Open2766-27052021-01-0111839110.1089/REGEN.2021.0015P13K/AKT/mTOR Pathway-Based Novel Biomarkers for Breast CancerVarruchi Sharma0Anil Panwar1Anil K. Sharma2Department of Biotechnology, Sri Guru Gobind Singh CollegeDepartment of Molecular Biology, Biotechnology & Bioinformatics, College of Basic Sciences & Humanities, CCS Haryana Agriculture UniversityDepartment of Biotechnology, M.M. (Deemed to be University)Background: Breast cancer has been the most recurrent frequent cause of cancer-related deaths in women in India and all around the world. The treatment options have been reportedly more effective in terms of cure at the initial stages of diagnosis, while at the advanced stages, the treatment still remains a great clinical challenge. Many targeted therapies have been reported earlier, which have given impetus to find novel therapies that may lead to increased survival rates in breast cancer patients. Methodology: The available literature using PubMed, Scopus and Google Scholar database was thoroughly reviewed using the keywords: breast cancer; P13K/AKT/mTOR; inhibitors; therapeutics; biomarkers and diagnosis. This narrative review of all the relevant papers with significant citations leads the authors to greater insight into the potential therapeutics against breast cancer. Results: In most breast cancers, the essential phosphoinositide-3-kinase/AKT/ mammalian rapamycin target (PI3K/AKT/mTOR) signalling pathway has reportedly been triggered, leading to excessive cell growth and tumor formation. The targeting of this important pathway is, therefore, an area of wide-clinical interest, particularly in the breast cancer treatment. Taking these details into account, the current review has reviewed preclinical and clinical studies where a variety of PI3K/Akt/mTOR pathway inhibitors (acting at different levels) have been used either alone or in conjunction with other cancer treatment agents. Conclusion: This review includes a detailed understanding of the structure and regulation/deregulation of mTOR, in addition to targeted therapies and the role of mTOR inhibitory drugs in the treatment of breast cancer, along with first and second generations PI3K/AKT/mTOR pathway inhibitorshttps://www.liebertpub.com/doi/full/10.1089/REGEN.2021.0015Breast cancerP13K/AKT/mTORinhibitorstherapeuticsbiomarkersdiagnosis |
| spellingShingle | Varruchi Sharma Anil Panwar Anil K. Sharma P13K/AKT/mTOR Pathway-Based Novel Biomarkers for Breast Cancer Re:GEN Open Breast cancer P13K/AKT/mTOR inhibitors therapeutics biomarkers diagnosis |
| title | P13K/AKT/mTOR Pathway-Based Novel Biomarkers for Breast Cancer |
| title_full | P13K/AKT/mTOR Pathway-Based Novel Biomarkers for Breast Cancer |
| title_fullStr | P13K/AKT/mTOR Pathway-Based Novel Biomarkers for Breast Cancer |
| title_full_unstemmed | P13K/AKT/mTOR Pathway-Based Novel Biomarkers for Breast Cancer |
| title_short | P13K/AKT/mTOR Pathway-Based Novel Biomarkers for Breast Cancer |
| title_sort | p13k akt mtor pathway based novel biomarkers for breast cancer |
| topic | Breast cancer P13K/AKT/mTOR inhibitors therapeutics biomarkers diagnosis |
| url | https://www.liebertpub.com/doi/full/10.1089/REGEN.2021.0015 |
| work_keys_str_mv | AT varruchisharma p13kaktmtorpathwaybasednovelbiomarkersforbreastcancer AT anilpanwar p13kaktmtorpathwaybasednovelbiomarkersforbreastcancer AT anilksharma p13kaktmtorpathwaybasednovelbiomarkersforbreastcancer |